Earnings season rolls into a high-impact week ahead, with results due from a broad cross-section of the market spanning Big Tech, semiconductors, healthcare, energy, consumer, REITs, and financials.
Mega-cap tech will be in sharp focus as Amazon (AMZN), Alphabet (GOOG) (GOOGL), Palantir (PLTR), Advanced Micro Devices (AMD), QUALCOMM (QCOM), Super Micro Computer (SMCI), Fortinet (FTNT), Skyworks Solutions (SWKS), NXP Semiconductors (NXPI), Snap (SNAP), Roblox (RBLX), Take-Two Interactive (TTWO), and Strategy (MSTR) report, offering fresh insight into AI spending, cloud demand, advertising trends, and enterprise budgets.
Healthcare and biotech updates are set to come from Pfizer (PFE), AbbVie (ABBV), Merck (MRK), Bristol-Myers Squibb (BMY), Eli Lilly (LLY), Novo Nordisk (NVO), Amgen (AMGN), GSK (GSK), Biogen (BIIB), and Omega Healthcare Investors (OHI), keeping drug pipelines, pricing, and margin trends in focus.
Consumer and media names include Walt Disney (DIS), PayPal (PYPL), PepsiCo (PEP), Chipotle Mexican Grill (CMG), Philip Morris International (PM), Uber Technologies (UBER), and T-Mobile US (TMUS), providing signals on discretionary spending and pricing power.
Energy and materials will be represented by ConocoPhillips (COP), Phillips 66 (PSX), Enterprise Products Partners (EPD), MPLX (MPLX), Suncor Energy (SU), Barrick Mining (B), Archer-Daniels-Midland (ADM), and Canopy Growth (CGC) alongside Aurora Cannabis (ACB).
The real estate and financial landscape round out the week with Simon Property Group (SPG), Digital Realty Trust (DLR), Crown Castle (CCI), Prudential Financial (PRU), Rithm Capital (RITM), and Ares Capital (ARCC).
Altogether, the lineup offers a comprehensive read on earnings momentum across nearly every major segment of the global economy.
Below is a rundown of major quarterly updates anticipated in the week of February 2 to February 6:
Monday, February 2
Walt Disney (DIS)
Disney (DIS) is set to report FQ1 results before the market opens Monday, with Street estimates pointing to a ~10% Y/Y decline in profits. Despite near-term earnings pressure, the broader investment narrative remains constructive.
Beyond earnings, Disney continues to expand its global footprint, moving ahead with plans for its seventh theme park resort and its first in the Middle East at Yas Island, Abu Dhabi. The project, announced in May 2025, reinforces the company’s long-term parks strategy.
Just days before its results, Seeking Alpha’s Quant Rating briefly shifted from Strong Buy to Hold before returning to Buy, while Wall Street analysts continue to rate the stock a Buy.
SA contributor Juxtaposed Ideas reiterates a bullish stance, citing strong FY26–FY27 EPS growth guidance and attractive valuations that suggest meaningful upside.
The author highlights that operationally, Disney is benefiting from resilient theme park performance despite competitive headwinds, solid theatrical momentum from franchises like Avatar and Zootopia 2, and improving DTC fundamentals driven by subscriber growth and expanding ARPUs. Longer term, monetization opportunities via gaming and commerce add optionality.
A healthier balance sheet, rising share repurchases, and a growing dividend further support the thesis, while improving technical indicators hint at a potential breakout after a prolonged sideways phase since mid-2022, says the author.
- Consensus EPS Estimates: $1.58
- Consensus Revenue Estimates: $25.60B
- Earnings Insight: Disney has topped EPS expectations for 8 straight quarters, missing revenue expectations in 50% of those reports.
Also reporting: Palantir Technologies (PLTR), Simon Property Group (SPG), NXP Semiconductors N.V. (NXPI), Tyson Foods (TSN), Two Harbors Investment (TWO), Teradyne (TER), Physicians Realty Trust (DOC), and more.
Tuesday, February 3
Pfizer (PFE)
Pfizer (PFE) is scheduled to report Q4 results before the market opens Tuesday, with Wall Street forecasting Y/Y declines in both revenue and profits.
The print comes amid ongoing portfolio reshaping, including Pfizer’s recent decision to divest its equity stake in ViiV Healthcare, the HIV-focused business majority owned by GSK (GSK).
Despite near-term pressure, analyst views remain split. Sell-side analysts continue to rate the stock a Buy, while Seeking Alpha’s Quant Rating is even more bullish at Strong Buy.
SA author ALLKA Research argues Pfizer remains firmly in the “green zone” into 2026, pushing back against retail concerns around the looming loss of exclusivity for blockbusters like Xeljanz and Ibrance over 2026–2028. The bullish case rests on Pfizer’s oncology and vaccine pipeline, alongside potentially best-in-class GLP-1/amylin candidates (MET-097i / MET-233i). Valuation also stands out: PFE trades at just ~8.5x forward non-GAAP earnings, well below peers such as AbbVie, Merck, and Eli Lilly, while offering a dividend yield north of 6%. With rate cuts expected in 2026, proponents see the risk-reward as compelling.
On the other side, SA Investing Group Leader Envision Research maintains a Sell, citing persistent margin and growth headwinds. Pfizer’s 2026 guidance implies continued Y/Y declines, with revenue and EPS midpoints of $61B and $2.90, respectively. Elevated debt, paused buybacks, mild dilution, and limited near-term payoff from strategic shifts weigh on the bear thesis.
- Consensus EPS Estimates: $0.57
- Consensus Revenue Estimates: $16.82B
- Earnings Insight: Pfizer has beaten EPS estimates in a straight 8 quarters, exceeding revenue estimates in 6 of those reports.
Also reporting: Advanced Micro Devices (AMD), PayPal (PYPL), Merck & Co. (MRK), Enterprise Products Partners L.P. (EPD), and PepsiCo. (PEP), Amgen (AMGN), Lumen Technologies (LUMN), Skyworks Solutions (SWKS), Prudential Financial (PRU), Enphase Energy (ENPH), Chipotle Mexican Grill (CMG), Corteva (CTVA), Suncor Energy (SU), Digital Turbine (APPS), fuboTV (FUBO), Archer-Daniels-Midland (ADM), Emerson Electric (EMR), MPLX LP (MPLX), Electronic Arts (EA), Marathon Petroleum (MPC), Clorox (CLX), Mondelez International (MDLZ), Take-Two Interactive Software (TTWO), Illinois Tool Works (ITW), and more.
Wednesday, February 4
Alphabet (GOOG) (GOOGL)
Alphabet (GOOG) (GOOGL) is set to report its Q4 earnings after the market closes Wednesday, with analysts expecting ~23% Y/Y earnings growth and ~16% revenue growth.
The stock is up an impressive ~72% over the past year, keeping it firmly in focus this earnings season.
Wall Street remains firmly bullish, maintaining Strong Buy ratings on expectations of continued upside. Seeking Alpha’s Quant Rating, however, strikes a more cautious tone with a Hold, flagging valuation concerns after the sharp run-up.
On the bullish side, SA contributor Michael Del Monte reiterates a Buy with a $331 price target, pointing to accelerating Gemini AI adoption and expanding Google Cloud margins. Alphabet’s relative outperformance among hyperscalers is increasingly tied to its Gemini capabilities and steady improvement in Cloud profitability. Expectations are building for higher capital deployment (~$29B) and potentially ~44% growth in Google Cloud in early 2025.
The bear case centers on valuation and risk/reward. SA contributor Paul Franke downgraded the stock to Hold, noting that shares have nearly doubled in a year and appear fully priced. Valuation multiples sit at multi-decade highs, with EV/EBITDA near 26x and FCF yield compressed to ~1.8%. Fading technical momentum, elevated insider selling, and sensitivity to any slowdown in AI adoption add to near-term caution.
- Consensus EPS Estimates: $2.64
- Consensus Revenue Estimates: $111.45B
- Earnings Insight: Google has topped EPS expectations in a consecutive 8 quarters, beating revenue estimates in 7 of those reports.
Also reporting: AbbVie (ABBV), Qualcomm (QCOM), Aurora Cannabis (ACB), Uber Technologies (UBER), Snap (SNAP), Omega HealthCare Investors (OHI), Ares Capital (ARCC), Phillips 66 (PSX), Eli Lilly & Co. (LLY), Crown Castle International (CCI), Brookfield Asset Management (BAM), T. Rowe Price Group (TROW), Novo Nordisk A/S (NVO), AFLAC (AFL), Metlife (MET), Yum! Brands (YUM), Arm Holdings (ARM), GE HealthCare (GEHC), and more.
Thursday, February 5
Amazon.com (AMZN)
E-commerce and cloud giant Amazon (AMZN) is scheduled to report its Q4 earnings on Thursday after the close, with Wall Street forecasting ~4% Y/Y profit growth on ~12% revenue growth, as e-commerce resilience and AWS momentum remain in focus.
Ahead of the print, Amazon has been back in the AI headlines. Reports suggest AMZN is in talks to invest up to $50B in OpenAI, potentially becoming the largest contributor to its current fundraising round. The discussions, reportedly led by CEO Andy Jassy and OpenAI CEO Sam Altman, follow earlier reports that Amazon, Microsoft (MSFT), and Nvidia (NVDA) are collectively exploring investments of up to $60B, underscoring the escalating AI arms race among hyperscalers.
On the cost side, Amazon announced plans to cut ~16,000 corporate roles as it continues to streamline operations, signaling renewed discipline after years of heavy expansion.
From a ratings perspective, sell-side analysts largely maintain a Strong Buy, while Seeking Alpha’s Quant Rating recently shifted to Hold from Strong Buy, reflecting valuation and capital intensity concerns despite strong long-term fundamentals.
SA Investing Group Leader Dhierin Bechai says Amazon remains a Strong Buy, with a $319.56 price target and 32% upside, despite recent underperformance versus the S&P 500. Cloud, AI, and the Kuiper satellite project position AMZN to capitalize on mega trends, driving long-term revenue and margin growth. High capital intensity from AI and cloud investments pressures free cash flow, but robust demand and customer contracts underpin near-term ROI. Applying a conservative 16.5x EV/EBITDA multiple, AMZN still offers attractive upside, with margins and free cash flow expected to improve by 2026.
- Consensus EPS Estimates: $1.94
- Consensus Revenue Estimates: $211.17B
- Earnings Insight: Amazon has beaten EPS expectations in all the past 8 quarters and revenue 7 times in that time span.
Also reporting: Bristol Myers Squibb (BMY), Shell (SHEL), Barrick Gold (B), ConocoPhillips (COP), Roblox (RBLX), Peloton Interactive (PTON), Illumina (ILMN), SiriusXM Holdings (SIRI), Digital Realty Trust (DLR), Carrier Global (CARR), Cummins (CMI), Fortinet (FTNT), Ventas (VTR), Cardinal Health (CAH), Atlassian (TEAM), Affirm Holdings (AFRM), CIGNA (CI), KKR & Co. L.P. (KKR), BCE (BCE), Bloom Energy (BE), Peabody Energy (BTU), Strategy (MSTR), Tapestry (TPR), Reddit (RDDT), and more.
Friday, February 6
Philip Morris International (PM)
Philip Morris International (PM) is set to report Q4 earnings premarket on Friday, coming a week after peer Altria (MO) delivered mixed results. Analysts are projecting ~10% Y/Y earnings growth, with investors closely watching the trajectory of smoke-free products.
A key recent development is PM’s presentation to the FDA’s Tobacco Products Scientific Advisory Committee, seeking Modified Risk Tobacco Product (MRTP) status for its nicotine pouch ZYN. If approved, ZYN would become the first nicotine pouch in the U.S. to receive an MRTP designation, allowing PM to market it as a lower-risk alternative to cigarettes, potentially accelerating the shift toward smokeless nicotine.
Ahead of its presentation at the Morgan Stanley Global Consumer & Retail Conference in December, PM reaffirmed its FY2025 profit guidance, unchanged from its prior quarterly update.
The stock has gained ~37% over the past year and ~11% so far in 2026, with both sell-side analysts and Seeking Alpha’s Quant Rating assigning a Buy.
SA contributor Ironside Research highlights PM’s strong execution, noting a 108% total return since January 2024, more than double the S&P 500. The rally has been driven primarily by robust ZYN growth, with nicotine pouch volumes up 36% Y/Y. Management also clarified that Q3’s $100M hit in the Americas segment was a one-off promotional event. While PM now trades closer to fair value, further upside hinges on upgraded guidance, supporting a continued Buy stance.
- Consensus EPS Estimates: $1.70
- Consensus Revenue Estimates: $10.40B
- Earnings Insight: The company has beaten EPS and revenue expectations in 7 of the past 8 quarters.
Also reporting: Canopy Growth (CGC), Biogen (BIIB), Under Armour (UA) (UAA), Plains All American Pipeline, L.P. (PAA), Toyota Motor (TM), Newell Brands (NWL), Centene Corporation (CNC), Carlyle Group L.P. (CG), Proto Labs (PRLB), AutoNation (AN), and more.